This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna Rallies on Encouraging Coronavirus Vaccine Study Data
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
Expect Further Rally in Nasdaq-100 ETFs as Moderna Joins
by Sanghamitra Saha
Moderna shares have gained a whopping 283.6% this year due to successful early-stage clinical trials for COVID-19 vaccine, winning a place on the Nasdaq-100 with the company's sheer success.
Markets Bet Big on Coronavirus Vaccine Stocks: 3 Front Runners
by Tirthankar Chakraborty
As investors cheer signs of progress in COVID-19 vaccine development, here're three stocks that are worth keeping an eye on.
Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.
Moderna Rises on Bullish Sentiments for Coronavirus Vaccine
by Zacks Equity Research
Moderna's (MRNA) progress with its coronavirus vaccine is boosting the company's growth prospects. Some analysts expect its coronavirus vaccine to generate more than $5 billion in sales.
Pfizer/BioNTech's Coronavirus Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
Pfizer's (PFE) shares jump after FDA grants fast track status to two coronavirus vaccine candidates
Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight
by Tirthankar Chakraborty
Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.
FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus
by Ritujay Ghosh
Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Moderna Collaborates to Support Coronavirus Vaccine Supply
by Zacks Equity Research
Moderna (MRNA) signs manufacturing deal with Europe-based pharma company, Rovi, to support supply of its coronavirus vaccine in ex-US markets.
Moderna Completes Enrollment in Phase II Coronavirus Study
by Zacks Equity Research
Moderna (MRNA) is progressing well with its coronavirus vaccine development. It completes enrollment in a phase II study and finalizes phase III study protocol.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $61.58, marking a +0.8% move from the previous day.
Glaxo Signs Another Deal to Develop a Coronavirus Vaccine
by Zacks Equity Research
Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.
Novovax Up on $1.6B Federal Funding for Coronavirus Program
by Zacks Equity Research
Novovax (NVAX) is evaluating a coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. A pivotal study is due to start in the fourth quarter.
4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine
by Ritujay Ghosh
The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.
Moderna Shares Lose Momentum After Meteoric Rise: Here's Why
by Zacks Equity Research
The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.
Company News for Jul 6, 2020
by Zacks Equity Research
Companies In The News Are: TSLA, ALK, MRNA, BA.
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen
by Sweta Jaiswal, FRM
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
Pfizer Reports Encouarging Data From Coronavirus Program
by Zacks Equity Research
Pfizer (PFE) announces promising preliminary data on a vaccine candidate from its early-stage coronavirus program under which it is developing four mRNA-based vaccine candidates.
Are Options Traders Betting on a Big Move in Moderna (MRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
FDA Issues Guidance for Coronavirus Vaccine Developers
by Kinjel Shah
Around a dozen companies are developing a vaccine for the deadly coronavirus disease.
Investing Strategies for 2H Amid Coronavirus Resurgence
by Sanghamitra Saha
Investors should prepare well before investing in 2H as many market watchers are suspecting rising volatility ahead.
Vaxart's Oral Coronavirus Vaccine Candidate Gets Chosen by OWS
by Zacks Equity Research
Vaxart's (VXRT) oral COVID-19 vaccine candidate is picked for a non-human primate challenge study as part of the Operation Warp Speed initiative to rapidly develop a vaccine against SARS-CoV-2.
Top Leveraged ETFs of Last Week
by Sanghamitra Saha
Leveraged gold miners and treasury ETFs gained last week despite a market crash.